From the Guidelines
The prognosis for stage III duodenal adenocarcinoma is generally poor, with a 5-year survival rate of approximately 20-30%. This stage indicates that the cancer has spread beyond the duodenum to nearby lymph nodes but has not yet metastasized to distant organs.
Treatment Overview
Treatment typically involves surgical resection, and the use of adjuvant chemotherapy has been shown to improve survival rates in some cases, as demonstrated by a study where a treatment plan of pre- and postoperative epirubicin, cisplatin, and continuous i.v. infusion of 5-fluorouracil (5-FU) significantly improved 5-year survival 1.
Key Factors Influencing Prognosis
Factors that influence prognosis include:
- The patient's overall health status
- Age
- Tumor characteristics (such as differentiation and lymphovascular invasion)
- Completeness of surgical resection
- Response to chemotherapy Regular follow-up with imaging studies and tumor marker assessments is essential to monitor for recurrence. Despite aggressive treatment, recurrence rates remain high, with most occurring within the first two years after treatment. Patients should be monitored closely during this period, as early detection of recurrence may allow for additional therapeutic interventions.
From the Research
Prognosis of Stage III Duodenal Adenocarcinoma
The prognosis of stage III duodenal adenocarcinoma is generally poor, with a 5-year overall survival rate ranging from 10.6% to 64.9% [ 2, 3 ].
Factors Affecting Prognosis
Several factors can affect the prognosis of stage III duodenal adenocarcinoma, including:
- Lymph node positivity [ 3 ]
- N stage [ 3 ]
- TNM stage [ 3 ]
- Carbohydrate antigen 19-9 (CA19-9) positivity [ 3 ]
- T status [ 4 ]
- Curative resection [ 2, 5 ]
Treatment Options
Treatment options for stage III duodenal adenocarcinoma include:
Survival Outcomes
The median overall survival for stage III duodenal adenocarcinoma ranges from 14.4 months to 49 months [ 2, 6 ]. The 5-year overall survival rate ranges from 10.6% to 64.9% [ 2, 3 ].